Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5705535 | Ophthalmology | 2016 | 7 Pages |
Abstract
At month 24, there were significant visual and anatomic improvements in both groups, with subjects in the 0.5 mg RBZ group gaining more vision. Visual and anatomic gains achieved at month 6 were largely maintained through month 24. No new safety events were identified. In this study population, 2.0 mg RBZ does not appear to provide additional benefit over 0.5 mg RBZ.
Keywords
RBZDMEFDACFTPRNETDRSSD OCTBCVADiabetic macular edemaOctbest-corrected visual acuityOptical coherence tomographySpectral-domain optical coherence tomographyVisual acuityearly treatment diabetic retinopathy studyranibizumabFood and Drug Administrationcentral foveal thicknesspro re nataVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Yasir J. MBBS, Mohammad Ali MBBS, David MD, David MD, Ron MD, Michael MD, Dennis MD, Lawrence MD, Muhammad MBBS, Peter A. MD, Quan Dong MD, MSc, Diana V. MD,